What is the role of Braftovi (encorafenib) and Mektovi (binimetinib) in combination for unresectable or metastatic melanoma?

The FDA recently approved Braftovi (encorafenib) and Mektovi (binimetinib) in combination for unresectable or metastatic melanoma. When would they be preferentially used?

Answer from: Medical Oncologist at Academic Institution

This is a very timely question with the FDA approval of the encorafenib/binimetinib regimen. There are no randomized head-to-head trials comparing BRAF/MEK inhibitors so there are no clear data to guide which regimen is the most effective. The COLUMBUS trial reported the longest OS, PFS with the e...

Comments

Medical Oncologist
Thanks a lot for your answer. It is very helpful.

Please select the option that best describes you:

What is the role of Braftovi (encorafenib) and Mektovi (binimetinib) in combination for unresectable or metastatic melanoma?

Related Questions